Our two lead programs are currently in Phase 1 – VENT-02, a brain-penetrant NLRP3 inhibitor and VENT-03, a first-in-class cGAS inhibitor.
We are a clinical-stage biopharmaceutical company advancing a pipeline of novel medicines in immunology, inflammation, and neurology.